A novel method for the determination of basal gene expression of tissue-specific promoters: An analysis of prostate-specific promoters

Henk G. Van Der Poel, John McCadden, Gerald W. Verhaegh, Mark Kruszewski, Fernando Ferrer, Jack A. Schalken, Michael Carducci, Ronald Rodriguez

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Because the toxicity of suicide gene therapeutics is directly related to basal promoter activity, we developed an assay to test for promoter "leakiness" using a diphtheria toxin mutant. Sequences of 15 prostate-specific gene promoter constructs were cloned in an expression plasmid (pBK; Stratagene, La Jolla, CA) backbone driving expression of an attenuated mutant of diphtheria toxin A (tox176). Low expression levels of the DT-tox176 result in significant protein synthesis inhibition reflected by a decreased expression of the luciferase activity of a simultaneously transfected CMV luciferase construct. ID50 (dose of plasmid with 50% luciferase inhibition) was calculated for each promoter construct in different cell lines. Highest transactivational activity (ID50 <75 ng) was found for the CMV promoter in all cell lines, which is in agreement with the dual luciferase assay findings. Unlike the dual luciferase findings, however, the DT-tox176 assay showed protein inhibition of CN65 (PSA promoter/enhancer) and PSE-hK2 (PSA enhancer and basal human kallikrein 2 promoter) in HEK293 and DLD cells indicating "leakiness" of these promoter constructs. Low basal promoter activity in nonprostate cell lines was found for the minimal PSA promoter, hK2, DD3, and OC promoters. The DT-tox176 assay can better predict basal promoter activity compared to less sensitive dual luciferase assay.

Original languageEnglish (US)
Pages (from-to)927-935
Number of pages9
JournalCancer Gene Therapy
Volume8
Issue number12
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Luciferases
Prostate
Gene Expression
Diphtheria Toxin
Cell Line
Plasmids
Tissue Kallikreins
HEK293 Cells
Suicide
Genes
Proteins
Inhibition (Psychology)

Keywords

  • Diphtheria toxin
  • Gene promoters
  • Gene therapy
  • Luciferase assay
  • Prostate cancer
  • Protein synthesis inhibition

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

A novel method for the determination of basal gene expression of tissue-specific promoters : An analysis of prostate-specific promoters. / Van Der Poel, Henk G.; McCadden, John; Verhaegh, Gerald W.; Kruszewski, Mark; Ferrer, Fernando; Schalken, Jack A.; Carducci, Michael; Rodriguez, Ronald.

In: Cancer Gene Therapy, Vol. 8, No. 12, 2001, p. 927-935.

Research output: Contribution to journalArticle

Van Der Poel, HG, McCadden, J, Verhaegh, GW, Kruszewski, M, Ferrer, F, Schalken, JA, Carducci, M & Rodriguez, R 2001, 'A novel method for the determination of basal gene expression of tissue-specific promoters: An analysis of prostate-specific promoters', Cancer Gene Therapy, vol. 8, no. 12, pp. 927-935. https://doi.org/10.1038/sj.cgt.7700385
Van Der Poel, Henk G. ; McCadden, John ; Verhaegh, Gerald W. ; Kruszewski, Mark ; Ferrer, Fernando ; Schalken, Jack A. ; Carducci, Michael ; Rodriguez, Ronald. / A novel method for the determination of basal gene expression of tissue-specific promoters : An analysis of prostate-specific promoters. In: Cancer Gene Therapy. 2001 ; Vol. 8, No. 12. pp. 927-935.
@article{47d576ff2eaa46e5a9d2c89a06a78669,
title = "A novel method for the determination of basal gene expression of tissue-specific promoters: An analysis of prostate-specific promoters",
abstract = "Because the toxicity of suicide gene therapeutics is directly related to basal promoter activity, we developed an assay to test for promoter {"}leakiness{"} using a diphtheria toxin mutant. Sequences of 15 prostate-specific gene promoter constructs were cloned in an expression plasmid (pBK; Stratagene, La Jolla, CA) backbone driving expression of an attenuated mutant of diphtheria toxin A (tox176). Low expression levels of the DT-tox176 result in significant protein synthesis inhibition reflected by a decreased expression of the luciferase activity of a simultaneously transfected CMV luciferase construct. ID50 (dose of plasmid with 50{\%} luciferase inhibition) was calculated for each promoter construct in different cell lines. Highest transactivational activity (ID50 <75 ng) was found for the CMV promoter in all cell lines, which is in agreement with the dual luciferase assay findings. Unlike the dual luciferase findings, however, the DT-tox176 assay showed protein inhibition of CN65 (PSA promoter/enhancer) and PSE-hK2 (PSA enhancer and basal human kallikrein 2 promoter) in HEK293 and DLD cells indicating {"}leakiness{"} of these promoter constructs. Low basal promoter activity in nonprostate cell lines was found for the minimal PSA promoter, hK2, DD3, and OC promoters. The DT-tox176 assay can better predict basal promoter activity compared to less sensitive dual luciferase assay.",
keywords = "Diphtheria toxin, Gene promoters, Gene therapy, Luciferase assay, Prostate cancer, Protein synthesis inhibition",
author = "{Van Der Poel}, {Henk G.} and John McCadden and Verhaegh, {Gerald W.} and Mark Kruszewski and Fernando Ferrer and Schalken, {Jack A.} and Michael Carducci and Ronald Rodriguez",
year = "2001",
doi = "10.1038/sj.cgt.7700385",
language = "English (US)",
volume = "8",
pages = "927--935",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - A novel method for the determination of basal gene expression of tissue-specific promoters

T2 - An analysis of prostate-specific promoters

AU - Van Der Poel, Henk G.

AU - McCadden, John

AU - Verhaegh, Gerald W.

AU - Kruszewski, Mark

AU - Ferrer, Fernando

AU - Schalken, Jack A.

AU - Carducci, Michael

AU - Rodriguez, Ronald

PY - 2001

Y1 - 2001

N2 - Because the toxicity of suicide gene therapeutics is directly related to basal promoter activity, we developed an assay to test for promoter "leakiness" using a diphtheria toxin mutant. Sequences of 15 prostate-specific gene promoter constructs were cloned in an expression plasmid (pBK; Stratagene, La Jolla, CA) backbone driving expression of an attenuated mutant of diphtheria toxin A (tox176). Low expression levels of the DT-tox176 result in significant protein synthesis inhibition reflected by a decreased expression of the luciferase activity of a simultaneously transfected CMV luciferase construct. ID50 (dose of plasmid with 50% luciferase inhibition) was calculated for each promoter construct in different cell lines. Highest transactivational activity (ID50 <75 ng) was found for the CMV promoter in all cell lines, which is in agreement with the dual luciferase assay findings. Unlike the dual luciferase findings, however, the DT-tox176 assay showed protein inhibition of CN65 (PSA promoter/enhancer) and PSE-hK2 (PSA enhancer and basal human kallikrein 2 promoter) in HEK293 and DLD cells indicating "leakiness" of these promoter constructs. Low basal promoter activity in nonprostate cell lines was found for the minimal PSA promoter, hK2, DD3, and OC promoters. The DT-tox176 assay can better predict basal promoter activity compared to less sensitive dual luciferase assay.

AB - Because the toxicity of suicide gene therapeutics is directly related to basal promoter activity, we developed an assay to test for promoter "leakiness" using a diphtheria toxin mutant. Sequences of 15 prostate-specific gene promoter constructs were cloned in an expression plasmid (pBK; Stratagene, La Jolla, CA) backbone driving expression of an attenuated mutant of diphtheria toxin A (tox176). Low expression levels of the DT-tox176 result in significant protein synthesis inhibition reflected by a decreased expression of the luciferase activity of a simultaneously transfected CMV luciferase construct. ID50 (dose of plasmid with 50% luciferase inhibition) was calculated for each promoter construct in different cell lines. Highest transactivational activity (ID50 <75 ng) was found for the CMV promoter in all cell lines, which is in agreement with the dual luciferase assay findings. Unlike the dual luciferase findings, however, the DT-tox176 assay showed protein inhibition of CN65 (PSA promoter/enhancer) and PSE-hK2 (PSA enhancer and basal human kallikrein 2 promoter) in HEK293 and DLD cells indicating "leakiness" of these promoter constructs. Low basal promoter activity in nonprostate cell lines was found for the minimal PSA promoter, hK2, DD3, and OC promoters. The DT-tox176 assay can better predict basal promoter activity compared to less sensitive dual luciferase assay.

KW - Diphtheria toxin

KW - Gene promoters

KW - Gene therapy

KW - Luciferase assay

KW - Prostate cancer

KW - Protein synthesis inhibition

UR - http://www.scopus.com/inward/record.url?scp=0035207031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035207031&partnerID=8YFLogxK

U2 - 10.1038/sj.cgt.7700385

DO - 10.1038/sj.cgt.7700385

M3 - Article

C2 - 11781655

AN - SCOPUS:0035207031

VL - 8

SP - 927

EP - 935

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 12

ER -